Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 104
- Registration Number
- NCT00767325
- Locations
- 🇬🇧
Local Institution, Leeds, North Yorkshire, United Kingdom
Safety Study of Abatacept to Treat Refractory Sarcoidosis
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 1
- Registration Number
- NCT00739960
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 13
- Registration Number
- NCT00705367
- Locations
- 🇨🇳
Local Institution, Shanghai, Shanghai, China
Phase IIIB Switching From Intravenous to Subcutaneous Study
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2015-03-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 123
- Registration Number
- NCT00663702
- Locations
- 🇺🇸
Rheumatology Associates Of N. Al, P.C., Huntsville, Alabama, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
🇺🇸Valerius Medical Group &Research Ctr. Of Greater Long Beach, Long Beach, California, United States
Pilot Open Label Clinical Trial With Abatacept in Ankylosing Spondylitis
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2008-02-26
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 30
- Registration Number
- NCT00558506
- Locations
- 🇩🇪
Charité University Medicine Berlin, Campus Benjamin-Franklin, Berlin, Germany
🇩🇪Rheumazentrum Ruhrgebiet, Herne, Germany
Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
- Conditions
- Interventions
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2018-02-26
- Target Recruit Count
- 97
- Registration Number
- NCT00556439
- Locations
- 🇺🇸
Hospital for Special Surgery, New York, New York, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Johns Hopkins Medical Center, Baltimore, Maryland, United States
Phase IIIB Subcutaneous Abatacept Monotherapy Study
- Conditions
- Interventions
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 119
- Registration Number
- NCT00547521
- Locations
- 🇺🇸
Columbia Arthritis Center, Columbia, South Carolina, United States
🇺🇸Boulder Medical Center, Boulder, Colorado, United States
🇺🇸Physicians East, Pa, Greenville, North Carolina, United States
Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 191
- Registration Number
- NCT00534313
- Locations
- 🇺🇸
Desert Medical Advances, Palm Desert, California, United States
🇺🇸Arthritis Clinic & Carolina Bone & Joint, Pa, Charlotte, North Carolina, United States
🇺🇸Boling Clinical Trials, Upland, California, United States
Phase IIIB Subcutaneous Missed Dose Study
- First Posted Date
- 2007-09-24
- Last Posted Date
- 2015-04-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 270
- Registration Number
- NCT00533897
- Locations
- 🇺🇸
Mountain State Clinical Research, Clarksburg, West Virginia, United States
🇺🇸Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸New England Research Associates, Llc, Trumbull, Connecticut, United States
A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis
- First Posted Date
- 2007-06-08
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 217
- Registration Number
- NCT00484289
- Locations
- 🇯🇵
Local Institution, Chiba-Shi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.